All filters
Videos
Baricitinib reverses HIV associated neurocognitive disorders and reservoir seeding in a SCID mouse model | Christina Gavegnano, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
State of the Art Lecture: Harnessing the immune system to eliminate and/or control HIV | Steven Deeks, MD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Barry-Wainberg DART Achievement Award Lecture: Overview of the research conducted at the Irsicaixa Foundation | Bonaventura Clotet, MD, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Cytotoxic agents | Markus Jörger, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Videos
Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MD
Presented at:
International Workshop on HBV Cure 2018
Videos
Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhD
Presented at:
International Workshop on HBV Cure 2018
Videos
What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2018
Videos
Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel Verdon
Presented at:
International Workshop on HBV Cure 2018
Videos
Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela Paulsen
Presented at:
International Workshop on HBV Cure 2018
Videos
Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhD
Presented at:
International Workshop on HBV Cure 2018
Videos
Antiviral effect of the RIG-I agonist, Inarigavir | Nezam Afdahl
Presented at:
International Workshop on HBV Cure 2018
Videos
Rationale for Modulating Adaptive Immunity | Robert Thimme
Presented at:
International Workshop on HBV Cure 2018